Halozyme Therapeutics (NASDAQ:HALO) Given New $90.00 Price Target at HC Wainwright

Halozyme Therapeutics (NASDAQ:HALO) had its target price boosted by HC Wainwright from $85.00 to $90.00 in a research report report published on Thursday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently commented on HALO. Morgan Stanley boosted their price target on Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an “overweight” rating in a report on Monday, August 18th. Zacks Research raised Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 2nd. JMP Securities increased their target price on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a “market outperform” rating in a report on Wednesday, August 6th. JPMorgan Chase & Co. lifted their price target on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the company a “neutral” rating in a report on Thursday, August 7th. Finally, Wall Street Zen cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 5th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $70.44.

Halozyme Therapeutics Stock Down 4.3%

HALO stock opened at $71.69 on Thursday. Halozyme Therapeutics has a 52 week low of $42.01 and a 52 week high of $79.50. The business has a 50-day simple moving average of $70.23 and a 200 day simple moving average of $61.92. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. The company has a market cap of $8.39 billion, a PE ratio of 16.41, a price-to-earnings-growth ratio of 0.41 and a beta of 1.16.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, beating the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The firm had revenue of $325.72 million for the quarter, compared to analyst estimates of $282.66 million. During the same period last year, the firm earned $0.91 EPS. The business’s quarterly revenue was up 40.8% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Sell-side analysts anticipate that Halozyme Therapeutics will post 4.73 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $63.51, for a total value of $1,270,200.00. Following the transaction, the chief executive officer directly owned 733,719 shares of the company’s stock, valued at $46,598,493.69. The trade was a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Nicole Labrosse sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total value of $1,514,200.00. Following the completion of the sale, the chief financial officer owned 24,306 shares in the company, valued at $1,840,207.26. The trade was a 45.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 88,227 shares of company stock worth $6,020,595 over the last ninety days. 2.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. DLD Asset Management LP acquired a new stake in Halozyme Therapeutics during the 2nd quarter worth about $650,250,000. Alliancebernstein L.P. boosted its position in shares of Halozyme Therapeutics by 4.8% during the 1st quarter. Alliancebernstein L.P. now owns 3,215,109 shares of the biopharmaceutical company’s stock valued at $205,156,000 after purchasing an additional 146,677 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its stake in Halozyme Therapeutics by 127.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 2,541,181 shares of the biopharmaceutical company’s stock worth $132,192,000 after purchasing an additional 1,425,674 shares during the period. Congress Asset Management Co. increased its holdings in Halozyme Therapeutics by 8.8% in the first quarter. Congress Asset Management Co. now owns 2,132,707 shares of the biopharmaceutical company’s stock worth $136,088,000 after purchasing an additional 172,971 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Halozyme Therapeutics by 4.9% in the first quarter. Dimensional Fund Advisors LP now owns 2,029,160 shares of the biopharmaceutical company’s stock valued at $129,478,000 after buying an additional 95,600 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.